Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors

Jennifer Berano Teh, Farah Abdulla, MD, Kelly Peng, Liezl Atencio, Alicia Gonzales, Meagan Echevarria, Alex Iukuridze, Alan Geller, Heeyoung Kim, Lennie Wong, PhD, Stephen J Forman, MD, Ryotaro Nakamura, MD, Badri Modi, MD, Saro H. Armenian, DO, MPH

Blood (2019) 134 (Supplement_1): 2011.

https://doi.org/10.1182/blood-2019-124993

Published: 2019

Journal Articles

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Micah Denay McCumber, BS, MS, Aaron Mark Wendelboe, PhD MS, Janis Campbell, PhD GISP, Kai Ding, PhD, Michele G Beckman, MPH, Nimia L Reyes, MD MPH, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3463.

https://doi.org/10.1182/blood-2019-130604

Published: 2019

Journal Articles

Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report

Pierre-Edouard Debureaux, Flore Sicre de Fontbrune, Carmem M. S. Bonfim, MD, Jean-Hugues Dalle, MD PhD, Nimrod Buchbinder, MD, Yves Bertrand, MD, Cecile Renard, MD, Edouard Forcade, MD, Juliana Fernandes, MD, Alexis Talbot, MD, Ricardo Pasquini, MD, Jean Soulier, MD PhD, Thierry Leblanc, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2498.

https://doi.org/10.1182/blood-2019-122007

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Laurie H Sehn, MD, Matthew J Matasar, MD, Christopher R. Flowers, MD MS, Manali Kamdar, MD MD, Andrew K McMillan, FRCP, Mark Hertzberg, MD MBBS, PhD, Sarit Assouline, MD, Tae Min Kim, MD PhD, Won Seog Kim, MD PhD, Muhit Ozcan, MD, Brandon Croft, PharmD, Jamie Hirata, PharmD, Ji Cheng, PhD, Grace Ku, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 4081.

https://doi.org/10.1182/blood-2019-123449

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Julie E Chang, MD, Vaishalee P. Kenkre, MD, Christopher D. Fletcher, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Kyungmann Kim, PhD, Grace Yi Chen, Kaitlin Chambers

Blood (2019) 134 (Supplement_1): 5470.

https://doi.org/10.1182/blood-2019-124489

Published: 2019

Journal Articles

Fanconi Anemia: A Paradigm for Understanding DNA Repair During Replication.

Agata Smogorzewska, MD PhD

Blood (2019) 134 (Supplement_1): SCI-32.

https://doi.org/10.1182/blood-2019-121229

Published: 2019

Journal Articles

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Kalyan Nadiminti, Abhishek A Mangaonkar, MBBS, Kimberly J. Langer, D.N.P., C.N.P., Shakila P Khan, MD, Vilmarie Rodriguez, MD, Naseema Gangat, MBBS, Michelle A Elliott, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mark Litzow, MD, William J Hogan, MB, BCh, Saad S. Kenderian, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 3300.

https://doi.org/10.1182/blood-2019-121742

Published: 2019

Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Blood (2019) 134 (Supplement_1): 4296.

https://doi.org/10.1182/blood-2019-128470

Published: 2019

Journal Articles

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Blood (2019) 134 (Supplement_1): 3116.

https://doi.org/10.1182/blood-2019-123205

Published: 2019

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas

Hidong Kim, MD, Laura Harper, MD, Thomas M. Habermann, MD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Patrick Johnston, Thomas E. Witzig, MD, Cristine Allmer, BS, Matthew J. Maurer, MS, James R. Cerhan, MD PhD, Jason Young, MD, Gita Thanarajasingam, MD

Blood (2018) 132 (Supplement 1): 5401.

https://doi.org/10.1182/blood-2018-99-117711

Published: 2018

Journal Articles

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Deborah M. Stephens, Hongli Li, MS, Heiko Schoder, MD, David J. Straus, MD, Craig H. Moskowitz, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Ann S. LaCasce, MD MSc, Paul Barr, MD, Michael V. Knopp, Eric D. Hsi, MD, John P. Leonard, MD, Brad S Kahl, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 929.

https://doi.org/10.1182/blood-2018-99-113034

Published: 2018

Journal Articles

Platelet (hem)ITAM Signaling Mediated Cancer-Associated Venous Thrombosis

Xia Wang, MD, Jingchang Wu, PhD, Haidi Gu, MD, Jun Qian, PhD, Changgeng Ruan, MD PhD, Yiming Zhao, PhD

Blood (2018) 132 (Supplement 1): 2509.

https://doi.org/10.1182/blood-2018-99-116220

Published: 2018

Journal Articles

Administration of BPX-501 Cells Following Αβ- T and B-Cell-Depleted HLA-Haploidentical HSCT in Children with Fanconi Anemia

Swati Naik, MBBS, Susanne H.C. Baumeister, MD, Victor Aquino, MD, Annalisa Ruggeri, MD PhD, Daria Pagliara, MD PhD, Melissa Aldinger, PharmD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2018-99-119534

Published: 2018

Journal Articles

Hypercalcemia- Leukocytosis Syndrome: A Rare Ominous Indicator in Lung Cancer

Taylor Hanson, Ravi Patel, DO, Nitasa Sahu, MD, Zain Ayaz, MD, Julie Caler, Pharm.D, Kirk Jones, Pharm.D, Rohit Jain, MBBS

Blood (2018) 132 (Supplement 1): 4966.

https://doi.org/10.1182/blood-2018-99-112705

Published: 2018

Journal Articles

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Juliette Soret-Dulphy, MD, Matthieu Resche-Rigon, MD PhD, Francoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Valérie Rolland-Neyret, Claude Capron, Sylvie Chevret, MD PhD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD

Blood (2018) 132 (Supplement 1): 581.

https://doi.org/10.1182/blood-2018-99-110785

Published: 2018

Journal Articles

Risk and Outcomes of Second Malignant Neoplasms in Chronic Myeloid Leukemia Survivors

Omer Jamy, Rehan Sarmad, MD MBBS, Luciano J. Costa, MD PhD

Blood (2017) 130 (Supplement 1): 350.

https://doi.org/10.1182/blood.V130.Suppl_1.350.350

Published: 2017

Journal Articles

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Abdul Rashid Shah, MD, Tariq Muzzafar, MBBS, Romana Asad, MD, Christine B Peterson, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Jan A. Burger, MD PhD, Nitin Jain, MD, Gautam Borthakur, MD, Maliha Khan, MD, Abhishek Chilkulwar, MD, Brion Randolph, MD, Lohith Gowda, MD, Michael J Keating

Blood (2017) 130 (Supplement 1): 5337.

https://doi.org/10.1182/blood.V130.Suppl_1.5337.5337

Published: 2017

NARROW

Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Fanconi Anemia: A Paradigm for Understanding DNA Repair During Replication.

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Platelet (hem)ITAM Signaling Mediated Cancer-Associated Venous Thrombosis

Administration of BPX-501 Cells Following Αβ- T and B-Cell-Depleted HLA-Haploidentical HSCT in Children with Fanconi Anemia

Hypercalcemia- Leukocytosis Syndrome: A Rare Ominous Indicator in Lung Cancer

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Risk and Outcomes of Second Malignant Neoplasms in Chronic Myeloid Leukemia Survivors

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only